cbdMD, Inc. Overview
Pro stress-test →cbdMD is one of the leading and most recognized cannabidiol (CBD) brands, offering a comprehensive line of U.S.-produced THC-free CBD products and an array of Farm Act-compliant Delta-9 products. The company operates Bluebird Botanicals, Paw CBD, ATRx Labs, and Herbal Oasis, a premium THC-infused functional social seltzer. The company is executing a consolidation strategy in the rapidly evolving hemp-derived wellness market.
Strategic Profile
Pro stress-test →cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions. In January 2026, cbdMD acquired substantially all assets of Bluebird Botanicals, a long-standing CBD brand. The company believes that increased regulatory clarity will favor well-capitalized, compliance-focused operators with strong quality and safety standards.
Competitive Landscape
Pro stress-test →cbdMD is a Charlotte, North Carolina-based producer and distributor of hemp-derived cannabidiol (CBD) products. The company competes in the fragmented CBD and hemp-derived wellness market against brands like Charlotte's Web, Elixinol, and other DTC and retail CBD players. cbdMD believes well-capitalized, compliance-focused operators with strong quality and safety standards will benefit from increased regulatory clarity. The Bluebird Botanicals acquisition strengthens competitive positioning through regulatory assets and brand portfolio diversification.
Industry Context
cbdMD, Inc. operates in Hemp-Derived Cannabidiol (CBD) Wellness Products & Distribution.
Key facts
Founded: 2018 · Headquarters: Charlotte, US · Revenue: $5.0M (Q1 FY2026) · Market cap: $9.7M